Impact of gastrointestinal adverse events on weight loss (STEP 13) Among participants on treatment at week 68 with a body weight assessment, the observed placebocorrected weight loss from baseline to week 68 for semaglutide 2.4 mg was 14.4 percentage points in the STEP 1 trial, 7.6 percentage points in the STEP 2 trial and 12.7 percentage points in the STEP 3 trial
Store Hepaglide injection in the refrigerator at 2-8C and do not freeze
The presence of obesity-related complications such as obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), or cardiovascular disease may justify longer treatment duration given the health benefits of sustained weight loss
Some compounded versions also include glycine or L-carnitine , which may support fat metabolism and muscle preservation during weight loss
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ozempic specifically for glycaemic management in type 2 diabetes, either as monotherapy when metformin is inappropriate or in combination with other glucose-lowering medications
